Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
Citation
Yekedüz, E., Ertürk, İ., Tural, D., Karadurmuş, N., Karakaya, S., Hızal, M., Arıkan, R., Arslan, Ç., Taban, H., Küçükarda, A., Öztaş, N. Ş., Sever, Ö. N., Uçar, G., Can, O., Nahit Şendur, M. A., Demirci, U., Kılıçkap, S., Çiçin, İ., Öksüzoğlu, B., Özgüroğlu, M., … Ürün, Y. (2021). Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future oncology (London, England), 10.2217/fon-2021-0717. Advance online publication.Abstract
Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.
